Metagenomi Statistics
Total Valuation
Metagenomi has a market cap or net worth of $62.05 million. The enterprise value is -$119.48 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Metagenomi has 37.38 million shares outstanding. The number of shares has increased by 372.04% in one year.
| Current Share Class | 37.38M |
| Shares Outstanding | 37.38M |
| Shares Change (YoY) | +372.04% |
| Shares Change (QoQ) | -0.77% |
| Owned by Insiders (%) | 11.03% |
| Owned by Institutions (%) | 24.93% |
| Float | 23.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.39 |
| Forward PS | 2.98 |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.85, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.85 |
| Quick Ratio | 5.73 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.93% and return on invested capital (ROIC) is -18.87%.
| Return on Equity (ROE) | -31.93% |
| Return on Assets (ROA) | -15.37% |
| Return on Invested Capital (ROIC) | -18.87% |
| Return on Capital Employed (ROCE) | -33.99% |
| Revenue Per Employee | $224,074 |
| Profits Per Employee | -$385,886 |
| Employee Count | 202 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.42M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.86% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.86% |
| 50-Day Moving Average | 1.58 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 53.47 |
| Average Volume (20 Days) | 296,929 |
Short Selling Information
The latest short interest is 2.40 million, so 6.43% of the outstanding shares have been sold short.
| Short Interest | 2.40M |
| Short Previous Month | 2.96M |
| Short % of Shares Out | 6.43% |
| Short % of Float | 10.32% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, Metagenomi had revenue of $45.26 million and -$77.95 million in losses. Loss per share was -$2.11.
| Revenue | 45.26M |
| Gross Profit | -57.62M |
| Operating Income | -87.69M |
| Pretax Income | n/a |
| Net Income | -77.95M |
| EBITDA | -82.20M |
| EBIT | -87.69M |
| Loss Per Share | -$2.11 |
Full Income StatementBalance Sheet
The company has $225.97 million in cash and $44.44 million in debt, giving a net cash position of $181.53 million or $4.86 per share.
| Cash & Cash Equivalents | 225.97M |
| Total Debt | 44.44M |
| Net Cash | 181.53M |
| Net Cash Per Share | $4.86 |
| Equity (Book Value) | 212.66M |
| Book Value Per Share | 5.69 |
| Working Capital | 193.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$102.07 million and capital expenditures -$2.49 million, giving a free cash flow of -$104.55 million.
| Operating Cash Flow | -102.07M |
| Capital Expenditures | -2.49M |
| Free Cash Flow | -104.55M |
| FCF Per Share | -$2.80 |
Full Cash Flow StatementMargins
Gross margin is -127.30%, with operating and profit margins of -193.73% and -172.21%.
| Gross Margin | -127.30% |
| Operating Margin | -193.73% |
| Pretax Margin | -184.18% |
| Profit Margin | -172.21% |
| EBITDA Margin | -181.60% |
| EBIT Margin | -193.73% |
| FCF Margin | n/a |
Dividends & Yields
Metagenomi does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -372.04% |
| Shareholder Yield | -372.04% |
| Earnings Yield | -125.62% |
| FCF Yield | -168.49% |
Analyst Forecast
The average price target for Metagenomi is $13.00, which is 683.13% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 683.13% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Metagenomi has an Altman Z-Score of -0.21 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.21 |
| Piotroski F-Score | 1 |